Immunotherapeutics
With a large-scale integration of biological modalities, we’ve made CAS BioFinder more relevant to biologists. We’ve added antibodies (Abs) and antibody-drug conjugates (ADCs) as special types of ligands with data features unique to these modalities, such as Ab sequences, antigens, CDRs, payloads, and linkers. This improvement to our coverage of therapeutic approaches enables you to pursue the best path for your research.
Drug Intelligence
You can explore ligands that are approved, investigational, or discontinued drugs with a new visual identification and overviews of regulatory status, clinical phase, indications, and targets. This information offers you a precursory assessment of the competitive landscape and allows you to focus on modalities that have cleared their path into the clinic. The capabilities include:
- Visual indication for ligands that are drugs, including the ability to narrow ligand sets based on their clinical phase and the approving authority.
- Drug intelligence details highlighted on the ligand page—including description, indications, targets, originator, and approval year—with links to drugs related via the active ingredient (e.g., salt forms).
- On the drug’s protein tab, the ability to delineate targets tested in the clinic from other pharmacological targets.
- On the drug’s disease tab, the ability to delineate diseases that are known indicators and condition adverse events from other diseases associated through pharmacology records.
Empirical Metabolites
We’ve added tens of thousands of empirical metabolic reactions. You can access expanded metabolites under the ligand page with a clear distinction between known and predicted species.